MA43051A - Polythérapie pour le traitement d'une du vhc - Google Patents
Polythérapie pour le traitement d'une du vhcInfo
- Publication number
- MA43051A MA43051A MA043051A MA43051A MA43051A MA 43051 A MA43051 A MA 43051A MA 043051 A MA043051 A MA 043051A MA 43051 A MA43051 A MA 43051A MA 43051 A MA43051 A MA 43051A
- Authority
- MA
- Morocco
- Prior art keywords
- polytherapy
- hcv
- treatment
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562234408P | 2015-09-29 | 2015-09-29 | |
| US201662299338P | 2016-02-24 | 2016-02-24 | |
| US201662353708P | 2016-06-23 | 2016-06-23 | |
| US201662365541P | 2016-07-22 | 2016-07-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43051A true MA43051A (fr) | 2018-08-08 |
Family
ID=58406227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043051A MA43051A (fr) | 2015-09-29 | 2016-09-29 | Polythérapie pour le traitement d'une du vhc |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20170087174A1 (fr) |
| EP (1) | EP3355991A1 (fr) |
| JP (1) | JP2018529777A (fr) |
| KR (1) | KR20180071276A (fr) |
| AU (1) | AU2016331073A1 (fr) |
| BR (1) | BR112018006206A2 (fr) |
| CA (1) | CA3000415A1 (fr) |
| EA (1) | EA201890818A1 (fr) |
| IL (1) | IL258228A (fr) |
| MA (1) | MA43051A (fr) |
| WO (1) | WO2017059147A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10004719B1 (en) | 2017-05-30 | 2018-06-26 | Taigen Biotechnology Co., Ltd. | Solid dispersion formulation |
| CA3121247A1 (fr) | 2018-12-03 | 2020-06-11 | Board Of Regents, The University Of Texas System | Analogues d'oligo-benzamide et leur utilisation dans le traitement du cancer |
| IL303390A (en) | 2020-12-03 | 2023-08-01 | Battelle Memorial Institute | Compositions of polymer nanoparticles and DNA nanostructures and methods for non-viral transport |
| WO2022216977A1 (fr) | 2021-04-07 | 2022-10-13 | Batelle Memorial Institute | Technologies de conception, de construction, de test et d'apprentissage rapides pour identifier et utiliser des vecteurs non viraux |
| WO2025072751A1 (fr) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Compositions de nanoparticules polymères pour l'expression in vivo de polypeptides |
| AU2024393766A1 (en) | 2023-12-08 | 2026-06-18 | Battelle Memorial Institute | Use of dna origami nanostructures for molecular information based data storage systems |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201532606A (zh) * | 2013-04-05 | 2015-09-01 | Alios Biopharma Inc | 使用化合物之組合治療c型肝炎病毒感染 |
| AU2014250762A1 (en) * | 2013-04-12 | 2015-10-29 | Achillion Pharmaceuticals, Inc. | Highly active nucleoside derivative for the treatment of HCV |
| AU2014265293B2 (en) * | 2013-05-16 | 2019-07-18 | Riboscience Llc | 4'-Fluoro-2'-methyl substituted nucleoside derivatives |
| WO2015110048A1 (fr) * | 2014-01-23 | 2015-07-30 | Sunshine Lake Pharma Co., Ltd. | Composés cycliques pontés comme inhibiteurs du virus de l'hépatite c, compositions pharmaceutiques et utilisations correspondantes |
| MA40844A (fr) * | 2014-11-10 | 2017-09-20 | Glaxosmithkline Ip No 2 Ltd | Compositions pharmaceutiques à action prolongée pour l'hépatite c |
| US10308937B2 (en) * | 2014-11-10 | 2019-06-04 | Glaxosmithkline Intellectual Property (No. 2) Limited | Combination long acting compositions and methods for Hepatitis C |
| US20180021361A1 (en) * | 2016-07-22 | 2018-01-25 | Janssen Pharmaceuticals, Inc. | Combination drug treatment for hepatitis c infection |
-
2016
- 2016-09-29 BR BR112018006206A patent/BR112018006206A2/pt not_active Application Discontinuation
- 2016-09-29 WO PCT/US2016/054561 patent/WO2017059147A1/fr not_active Ceased
- 2016-09-29 CA CA3000415A patent/CA3000415A1/fr not_active Abandoned
- 2016-09-29 JP JP2018536096A patent/JP2018529777A/ja active Pending
- 2016-09-29 EP EP16852646.5A patent/EP3355991A1/fr not_active Withdrawn
- 2016-09-29 EA EA201890818A patent/EA201890818A1/ru unknown
- 2016-09-29 AU AU2016331073A patent/AU2016331073A1/en not_active Abandoned
- 2016-09-29 KR KR1020187012074A patent/KR20180071276A/ko not_active Withdrawn
- 2016-09-29 US US15/281,050 patent/US20170087174A1/en active Pending
- 2016-09-29 MA MA043051A patent/MA43051A/fr unknown
-
2017
- 2017-07-25 US US15/659,464 patent/US20170319572A1/en not_active Abandoned
-
2018
- 2018-03-19 IL IL258228A patent/IL258228A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3000415A1 (fr) | 2017-04-06 |
| EA201890818A1 (ru) | 2018-09-28 |
| BR112018006206A2 (pt) | 2018-10-09 |
| US20170087174A1 (en) | 2017-03-30 |
| US20170319572A1 (en) | 2017-11-09 |
| IL258228A (en) | 2018-05-31 |
| WO2017059147A1 (fr) | 2017-04-06 |
| AU2016331073A1 (en) | 2018-05-10 |
| EP3355991A1 (fr) | 2018-08-08 |
| JP2018529777A (ja) | 2018-10-11 |
| KR20180071276A (ko) | 2018-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
| EP3641829A4 (fr) | Promédicament d'interféron pour le traitement du cancer | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| EP3233878A4 (fr) | Phosphoramidates pour le traitement du virus de l'hépatite b | |
| EP3452060A4 (fr) | Polythérapie pour le traitement du cancer | |
| MA45192A (fr) | Traitement d'association | |
| EP3474863A4 (fr) | Phosphoramidates pour le traitement du virus de l'hépatite b | |
| EP3455205A4 (fr) | Peptidomimétiques pour le traitement d'une infection à norovirus | |
| EP3347469A4 (fr) | Méthodes et compositions pour le traitement du glaucome | |
| MA42999A (fr) | Polythérapie pour le traitement de malignités | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| EP3322448A4 (fr) | Nouvelle approche pour le traitement du cancer par immunomodulation | |
| EP3325963A4 (fr) | Amélioration de l'estimation de globules | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| MA40867A (fr) | Méthodes pour le traitement d'infections virales à filoviridae | |
| EP3302379A4 (fr) | Compositions et méthodes pour le traitement du ptérygion | |
| EP3504187A4 (fr) | Utilisation de la pridopidine pour le traitement du déclin fonctionnel | |
| EP3380200A4 (fr) | Compositions pour le traitement des cheveux | |
| MA45492A (fr) | Vecteurs viraux pour le traitement de l'hyperactivité vésicale neurogène | |
| EP3359255A4 (fr) | Polythérapies pour le traitement du cancer | |
| EP3389645A4 (fr) | Combinaisons pour le traitement du cancer | |
| EP3634426A4 (fr) | Compositions pour le traitement d'une fibrose | |
| EP3380063A4 (fr) | Compositions pour le traitement des cheveux | |
| EP3334432A4 (fr) | Cerdulatinib pour le traitement du myélome | |
| EP3490561A4 (fr) | Combinaisons pour le traitement du cancer |